Can Fite Biopharma Ltd ADR (CANF) is a Healthcare · Biotechnology company listed on NYSE MKT. Price $2.26 (+0.89%), Market cap $0.01B, 52-week low–high $0.17 ~ $6.02.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It off
Financial statements, price targets, institutional (13F) holdings and related news for Can Fite Biopharma Ltd ADR are updated in real time on BlackAll Trade.
Can Fite Biopharma Ltd ADR trades at $2.26 (+0.89%). Real-time quotes and charts are available on BlackAll Trade.
Can Fite Biopharma Ltd ADR has a market cap of about $0.01B.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erec